1. Preclinical antitumor activity of S‐222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Issue 8 (August 2014) Authors: Tanaka, Hidekazu; Hirata, Michinari; Shinonome, Satomi; Wada, Toru; Iguchi, Motofumi; Dohi, Keiji; Inoue, Makiko; Ishioka, Yukichi; Hojo, Kanji; Yamada, Tomomi; Sugimoto, Tatsuya; Masuno, Koichi; Nezasa, Ken‐ichi; Sato, Norihito; Matsuo, Kenji; Yonezawa, Shuji; Frenkel, Eugene P.; Shichijo, Michi... Journal: Cancer science Issue: Volume 105:Issue 8(2014:Aug.) Page Start: 1040 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S‐222611, an oral reversible tyrosine kinase inhibitor of EGFR and HER2. A representative histological image of the colon treated with S‐222611 (25 mg/kg). Issue 8 (August 2014) Authors: Tanaka, Hidekazu; Hirata, Michinari; Shinonome, Satomi; Wada, Toru; Iguchi, Motofumi; Dohi, Keiji; Inoue, Makiko; Ishioka, Yukichi; Hojo, Kanji; Yamada, Tomomi; Sugimoto, Tatsuya; Masuno, Koichi; Nezasa, Ken‐ichi; Sato, Norihito; Matsuo, Kenji; Yonezawa, Shuji; Frenkel, Eugene P.; Shichijo, Michi... Journal: Cancer science Issue: Volume 105:Issue 8(2014:Aug.) Page Start: August cover Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗